If you were in TCR's editorial offices, surrounded by boxes of articles about acetylcholinesterase inhibitors (AChEI’s), you would quickly develop a sinking sensation. Not because the articles are so boring (though, in fact, they are); rather, because the pharmaceutical hype-sters are back on parade once again.

Plaques and Tangles, Amyloid deposits and Apo-E: Who can keep them straight? Unless you are a researcher, all you really need to know is how to diagnose dementia, and how to dose the acetylcholinesterase inhibitor du jour.

We'd all like to escape dementia in our old age. Over the past decade, numerous large scale epidemiological studies have been published singing the praises of a variety of agents that might prevent or delay dementia.

Dr. Agronin, as the "Director of Mental Health Services" at the Miami Jewish Home & Hospital for the Aged, what do you actually do?

Aloys Alzheimer was a German neurohistologist who was such a workaholic that he would examine brain tissue throughout the night, catching a few hours of sleep the next day before beginning all over again.

Dr. Renee Snow completed a geriatric psychiatry fellowship at Mclean Hospital and is now in private practice in North Andover, MA.

Lamictal (lamotrigine) has been approved! The only problem is that few people can quite comprehend what it's been approved for.

Topamax (topiramate), oddly enough, is a derivative of fructose. It is strange that one of the very few psychotropics to cause weight loss is closely related to sugar, but there you have it. It is only approved as adjunctive therapy for seizure treatment by the FDA.

Suddenly, we all have a colleague who is prescribing Trileptal (oxcarbazepine) for bipolar disorder, and who is claiming to have fabulous success.

Dr. Baldassano, as the Director of the Bipolar Outpatient Clinic of U Penn, how many patients with bipolar disorder do you typically evaluate in a given week?